Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.7523
+0.0583 (8.40%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $41.49 million as of April 15, 2025. Its market cap has decreased by -83.88% in one year.
Market Cap
41.49M
Enterprise Value
-76.07M
1-Year Change
-83.88%
Ranking
Category
Stock Price
$0.75
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $41.49M, a decrease of -94.86%. That is a compound annual growth rate of -47.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 15, 2025 | 41.49M | -40.87% |
| Dec 31, 2024 | 70.17M | -73.80% |
| Dec 29, 2023 | 267.79M | -6.83% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | 3.03B | 276.02% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 677.40B |
| UnitedHealth Group | 536.99B |
| Johnson & Johnson | 371.98B |
| AbbVie | 316.82B |
| Novo Nordisk | 294.67B |
| Abbott Laboratories | 221.92B |
| AstraZeneca | 210.97B |
| Novartis AG | 206.74B |